IRIS
CAVALLI, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.119
NA - Nord America 1.499
EU - Europa 1.146
SA - Sud America 620
AF - Africa 45
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 5.433
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.429
SG - Singapore 865
CN - Cina 618
BR - Brasile 513
SE - Svezia 404
HK - Hong Kong 315
IT - Italia 215
VN - Vietnam 174
DE - Germania 147
RU - Federazione Russa 107
FI - Finlandia 64
GB - Regno Unito 60
AR - Argentina 50
CA - Canada 41
IN - India 28
FR - Francia 26
ZA - Sudafrica 25
AT - Austria 24
PL - Polonia 23
EC - Ecuador 22
MX - Messico 20
NL - Olanda 18
IE - Irlanda 17
JP - Giappone 17
IQ - Iraq 16
ID - Indonesia 15
BD - Bangladesh 13
ES - Italia 13
TR - Turchia 12
CO - Colombia 10
MA - Marocco 8
PK - Pakistan 8
PY - Paraguay 8
VE - Venezuela 8
AZ - Azerbaigian 5
CL - Cile 5
UA - Ucraina 5
UZ - Uzbekistan 5
BG - Bulgaria 4
IR - Iran 4
KE - Kenya 4
PE - Perù 4
PH - Filippine 4
AE - Emirati Arabi Uniti 3
IL - Israele 3
TN - Tunisia 3
TW - Taiwan 3
BE - Belgio 2
BY - Bielorussia 2
EG - Egitto 2
EU - Europa 2
JO - Giordania 2
LT - Lituania 2
NO - Norvegia 2
NP - Nepal 2
RO - Romania 2
SV - El Salvador 2
AL - Albania 1
BH - Bahrain 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CU - Cuba 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
KI - Kiribati 1
KW - Kuwait 1
KZ - Kazakistan 1
MD - Moldavia 1
ME - Montenegro 1
MN - Mongolia 1
OM - Oman 1
PA - Panama 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.433
Salva come PNG Salva come JPEG
Città #
Singapore 352
Hong Kong 313
Dallas 285
Ashburn 187
Shanghai 170
Hefei 119
Lawrence 107
Princeton 107
New York 87
Beijing 82
Ho Chi Minh City 72
Milan 66
Los Angeles 58
Munich 52
Boardman 42
São Paulo 42
Moscow 39
Hanoi 35
Nuremberg 31
Helsinki 30
Turku 23
Denver 21
Rio de Janeiro 21
Atlanta 19
Guangzhou 19
Montreal 18
Poplar 18
Cesano Boscone 17
Dublin 17
Warsaw 17
Seattle 16
Johannesburg 15
Rome 14
Tokyo 13
Brooklyn 12
Chicago 12
London 12
Stockholm 12
Houston 11
Brasília 10
Lappeenranta 10
Santa Clara 10
Ankara 9
Orem 9
Amsterdam 8
Belo Horizonte 8
Chennai 8
Curitiba 8
Frankfurt am Main 8
The Dalles 8
Toronto 8
Vienna 8
Porto Alegre 7
Bologna 6
Buenos Aires 6
Falkenstein 6
Guayaquil 6
Haiphong 6
Manchester 6
Mexico City 6
Pune 6
Querétaro 6
Salvador 6
Xi'an 6
Baku 5
Bauru 5
Campinas 5
Can Tho 5
Cape Town 5
Hải Dương 5
Jakarta 5
Jiaxing 5
Mumbai 5
Quito 5
Saint Louis 5
Thái Bình 5
Tianjin 5
Uberlândia 5
Verona 5
Vitória 5
Wolfhagen 5
Baghdad 4
Biên Hòa 4
Boston 4
Brescia 4
Buffalo 4
Da Nang 4
Fortaleza 4
Londrina 4
Mestrino 4
Osasco 4
Phoenix 4
Quezon City 4
Rio Claro 4
San Francisco 4
San Jose 4
Sorocaba 4
São Bernardo do Campo 4
Tashkent 4
Vancouver 4
Totale 2.929
Salva come PNG Salva come JPEG
Nome #
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 133
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 111
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 108
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 95
Anakinra for patients with COVID-19: an updated systematic review and meta-analysis 91
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 87
A bitter effect: thrombocytopenia induced by a quinidine-containing beverage 86
A Novel Histiocytosis With Synovial and Skin Involvement 82
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 76
3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target 76
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 75
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 73
Advances in potential targeted therapies for Erdheim-Chester disease 72
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 72
Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies 71
Testosterone in males with COVID-19: A twelve-month cohort study 70
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 69
A virus-free cellular model recapitulates several features of severe COVID-19 69
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 67
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 66
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 66
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 65
Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients 65
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 64
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 64
Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis 62
Current treatment options and safety considerations when treating adult-onset Still’s disease 61
Autophagy and Protein Secretion 60
Anakinra for COVID-19: how to interpret elevations in serum liver enzymes 60
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 59
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 59
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 58
Autoimmune vitiligo is associated with gain-offunction by a transcriptional regulator that elevates expression of HLA-A∗02:01 in vivo 58
BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. 57
Anakinra therapy for non-cancer inflammatory diseases 57
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis 57
An enlightening scan 56
Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura 55
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 53
Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout 53
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 53
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial 53
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 52
Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis 51
ROLE OF TRAINED IMMUNITY AND IMMUNOMETABOLISM IN THE PATHOGENESIS OF ERDHEIM-CHESTER DISEASE 48
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease 47
Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? 47
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies 47
Anakinra for patients with COVID-19 – Authors' reply 47
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 47
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition 46
Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: A multicentre retrospective observational study 46
Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case 43
Testosterone in males with COVID-19: A 7-month cohort study 43
Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure 42
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 42
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis 42
Treating Pulmonary Silicosis by Blocking Interleukin 1 41
Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance 41
Myocarditis: An Interleukin-1-Mediated Disease? 41
Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab 40
Charcot's arthropathy of the spine 40
Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients 40
The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity 40
Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness 40
Treating Experimental Arthritis with the Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation 39
Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: The Role of Cardiac Magnetic Resonance 39
QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk 38
Priorities of biomedical research 38
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series 37
The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease 37
Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses 37
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 36
Diagnosing Erdheim-Chester disease 36
Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease 35
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 35
Letter by Campochiaro et al regarding article, “Clinical features, management, and outcomes of immune checkpoint inhibitor–Related cardiotoxicity” 35
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes 35
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement 35
Efficacy and safety of biological agents in adult-onset Still's disease 34
CARDIAC CINE MRI IN ERDHEIM-CHESTER DISEASE: DATA FROM A LARGE ITALIAN COHORT 34
The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. 34
Tocilizumab in patients with multisystem Erdheim–Chester disease 34
Hypertrophic cardiomyopathy secondary to hepatitis C virus-related vasculitis 34
Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis 34
Publications are not the finish line: Focusing on societal rather than publication impact 34
Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease (Arthritis Research and Therapy (2019) 21 (54) DOI: 10.1186/s13075-019-1843-9) 34
Suppression of inflammation and acquired immunity by IL-37 34
Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjögren's Syndrome 34
Erratum: Management of adult-onset Still's disease with interleukin-1 inhibitors: Evidence- And consensus-based statements by a panel of Italian experts (Arthritis Res Ther (2019) 21:275 DOI: 10.1186/s13075-019-2021-9) 33
MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo 33
Erdheim-Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancer 33
Charcot's arthropathy of the hip 33
Orthopnea with platydeoxia secondary to prominent Eustachian valve 32
Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature 32
Prevalence of Takayasu arteritis in young women with acute ischemic heart disease 32
Treating Life-Threatening Myocarditis by Blocking Interleukin-1 32
CLINICAL PRESENTATION OF ERDHEIM-CHESTER DISEASE: DATA FROM A COHORT 31
Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease 31
Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients 31
Totale 5.162
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.525
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.525
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202138 0 0 0 0 0 12 9 3 2 4 6 2
2021/2022128 1 0 32 31 11 11 4 2 21 3 8 4
2022/2023678 240 157 53 5 12 81 27 52 33 2 8 8
2023/2024496 17 40 60 43 48 72 23 52 5 8 40 88
2024/20251.782 179 31 37 51 67 122 197 221 346 232 134 165
2025/20262.447 345 390 410 786 388 128 0 0 0 0 0 0
Totale 5.664